# Viyash Scientific share price today (Viyash Scientific Ltd, NSE: VIYASH)

> Viyash Scientific share price today: ₹219.45 at the NSE close on 3 November 2026, up 2.3% in a year. Viyash Scientific (NSE: VIYASH) is worth ₹9,712 crore, trades at a P/E of 43.8 and has closed between ₹187.50 and ₹294.15 over the past 52 weeks. > Viyash Scientific Ltd's results are improving, while its P/E is near the low end of its own history over 9 years, higher than only 27% of past readings. VIYASH · Pharma - Animal · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/viyash-scientific-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹219.45 (+2.3% in a year)
- P/E: 43.8× (lower than 73% of the last 9 years)
- Revenue (Jun 2026): ₹946 Cr (+19.4% on a year ago)
- Profit (Jun 2026): ₹79.0 Cr (+113.5% on a year ago)
- Operating margin: 19.0% (+4.0 points on a year ago)
- ROCE: 13%, FY26

The main question: yearly earnings per share moved +336.6% while the share price moved +2.3%. ## What is the Viyash Scientific share price today? Viyash Scientific Ltd's share price was ₹219.45 at the close on 3 November 2026. It has been rising for 74 weeks. That is 6.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹188 and ₹294, and at that close it sat 30% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 9 weeks running. Over the last 11 years the share price moved +35% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Viyash Scientific this quarter? 1 points in one quarter, profit up on a year earlier for 11 quarters in a row (every quarter we can compare) and revenue up on a year earlier for 9 quarters in a row. 1. Promoters cut their stake by 12.1 points in one quarter From 61.3% to 49.2% in the September 2026 quarter. 2. Profit up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter profit was ₹79 crore, +113.5% on a year earlier. Why: Profit rose because the US human formulations business became much more profitable. Next results: check whether the remaining ESOP expense is around Rs 40 crore as management said. From the earnings call on 12 Aug 2026. 3. Revenue up on a year earlier for 9 quarters in a row In the June 2026 quarter revenue was ₹946 crore, +19.4% on a year earlier. Why: Revenue rose because animal-health products grew across regions on new launches and wider reach. Next results: check whether API orders come back and Vizag starts selling without another raw-material buying pause. From the earnings call on 12 Aug 2026. ## What are Viyash Scientific's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Viyash Scientific reported revenue of ₹946 crore, up 19.4% from ₹792 crore a year earlier, and a profit of ₹79.0 crore, up 113.5% from ₹37.0 crore. ### Viyash Scientific results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹946 crore | ₹792 crore | +19.4% |
| Profit | ₹79.0 crore | ₹37.0 crore | +113.5% |
| Earnings per share | ₹1.51 | ₹1.27 | +18.9% |
| Operating margin | 19.0% | 15.0% | +4.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Viyash Scientific's management discussed these results on a call held on 12 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Viyash Scientific share price history? Viyash Scientific closed at ₹219.45 on 3 November 2026, up 2.3% from ₹214.61 a year earlier (31 October 2025) and up 21.2% over five years. Its highest weekly close since March 2016 was ₹303.45 on 16 July 2021. ### Viyash Scientific share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹203.45 | +7.9% |
| 1 month ago · 1 Oct 2026 | ₹231.80 | −5.3% |
| 6 months ago · 30 Apr 2026 | ₹203.74 | +7.7% |
| 1 year ago · 31 Oct 2025 | ₹214.61 | +2.3% |
| 3 years ago · 3 Nov 2023 | ₹99.95 | +119.6% |
| 5 years ago · 4 Nov 2021 | ₹181.00 | +21.2% |
| 10 years ago · 4 Nov 2016 | ₹110.64 | +98.3% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹162.22 | +35.3% |
| Highest weekly close since March 2016 · 16 Jul 2021 | ₹303.45 | −27.7% |
| Lowest weekly close since March 2016 · 26 Oct 2018 | ₹45.05 | +387.1% |
| 52-week high (weekly close) · 3 Jul 2026 | ₹294.15 | −25.4% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹187.50 | +17.0% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Viyash Scientific? 3 Nov 2026: Viyash Scientific closed at ₹219.45, up 7.9% on the week and down 5.3% on the month. 12 Aug 2026: Viyash Scientific held its results call for April to June 2026. Management guided: Consolidated operating margin around 20-22%, with US human-formulations margin expected to continue at the current level. ### Earlier

- Results for April to June 2026: Revenue up 19.4% and profit up 113.5% on a year earlier. ## What dividend does Viyash Scientific pay? Viyash Scientific paid no dividend in the 12 months to 4 November 2026. The last was a dividend of ₹0.50 a share, ex-date 8 September 2021. ### Viyash Scientific dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 8 Sep 2021 | ₹0.50 | Dividend | 10 Sep 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 1 of 5 Of the last 5 financial years, years with an NSE dividend record

Not in its latest year. Viyash Scientific Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 3 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Viyash Scientific management say on the latest results call? On the call for April to June 2026, held on 12 August 2026, Viyash Scientific's management guided: Consolidated operating margin around 20-22%, with US human-formulations margin expected to continue at the current level. > “We are not going to acquire a business simply because our balance sheet is strong and we want to add numbers. That is not the plan.”
> Dr. Haribabu, on the call for April to June 2026

### What management guided

- FY27 revenue assumption approximately ₹4,000 crore, with API contributing 40-45%; overall API growth around 13-15% and animal-health API above 20%. - Europe growth 18-20% on an INR basis in FY27, excluding BioForLife; closing expected in 2-3 months and wider registrations over 18-24 months. - Remaining FY27 ESOP expense around ₹40 crore; goodwill amortization around ₹10-11 crore next quarter and then ceases from Q3. - Minority interests in the US and Spain planned for full acquisition within 2 years; minority share expected around 15-17% of profit. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/1527/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 12 August 2026.)

## What to watch in Viyash Scientific's next results? When Viyash Scientific reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: API order recovery and Vizag commercialization to translate into the next quarter's print without another raw-material-driven procurement pause. - What to check (from the call)
- API order recovery and Vizag commercialization to translate into the next quarter's print without another raw-material-driven procurement pause. - BioForLife closing to confirm agreement conditions and trigger the planned European registration and integration work. - ESOP and goodwill charges to show the expected reduction in reported profit drag and stronger profit conversion. - New animal-health tablet capacity to reach exhibit-batch readiness on schedule and support planned product launches. ## Which stock lists is Viyash Scientific on? Viyash Scientific is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 9732.82146618435](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Viyash Scientific profitable? Viyash Scientific Ltd earned ₹79.0 Cr of net profit in the Jun 2026 quarter, +113.5% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY26 profit was ₹225 Cr. That is 8.4% of the quarter's revenue. The same quarter a year earlier earned ₹37.0 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹225 Cr (+1,306.3% on the year before). Why profit moved: revenue changed +19.4% on a year earlier and the margin moved +4.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +451.7% and revenue +72.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Viyash Scientific make, and is it growing? Viyash Scientific Ltd reported ₹946 Cr of revenue in the Jun 2026 quarter, +19.4% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 10 years it has grown 18.9% a year on average. The last full year, FY26, came in at ₹3,420 Cr. The last four reported quarters add to ₹3,574 Cr. FY26 revenue was ₹3,420 Cr, +13.7% on the year before. Recent pace: the last four quarters grew +72.4% on average, against 18.9% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +52.9%, against +58.3% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +181.1%, against +336.7% a year (rolling over). ## How much of every ₹100 of sales does Viyash Scientific keep? Viyash Scientific Ltd's operating margin was 19.0% in the Jun 2026 quarter, 4.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 0.8% and 19.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +3.9 percentage points on the year while gross margin changed +2.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Viyash Scientific's profit turning into cash? Over the last 3 years, 244% of Viyash Scientific Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹323 Cr of operating cash against ₹225 Cr of profit. After ₹261 Cr of spending on assets, ₹62.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 244% of profit came in as cash: the cash cycle got 48 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 3.8× depreciation over three years. The next section checks what that spending is building. ## Where does Viyash Scientific's cash go? Viyash Scientific Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 160 days in FY26, up from 112 days in FY21. It spent ₹2,048 Cr on assets over the last 3 years. Customers take 112 days to pay, and stock sits for 188 days on average. At FY26 sales of ₹3,420 Cr, each day of that cycle ties up about ₹9.4 Cr, so roughly ₹1,499 Cr is tied up in the business at any time. FY26: customers took 112 days to pay and stock sat for 188 days, about 6.2 months of sales sitting as stock, for a full cycle of 160 days, longer than FY21's 112. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 188 days. Customers pay about 112 days after that. Suppliers are paid at 140 days. Together that makes the 160-day cycle. Spending on assets: ₹2,048 Cr over the last 3 years, against ₹535 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹70.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Viyash Scientific's P/E ratio, and how does it compare with its own history? Viyash Scientific Ltd's P/E is 43.8×, near the low end of its own history: it has been lower only 27% of the time. Its usual P/E (the middle reading) is 58.9×, over 9 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹5.76. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +336.6% while the price moved +2.3%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +3.9% a year; about +7.5% a year came from earnings growth and about −3.6 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 362% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Viyash Scientific business getting better or worse? Viyash Scientific Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Viyash Scientific earn on its capital? Viyash Scientific Ltd earned a ROCE of 13% in FY26. That is up from a low of −4% in FY14. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 6.6% net margin and 0.74× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 6.6% net margin × 0.74× asset turnover × 1.58× leverage (assets divided by equity) ≈ 7.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 362% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Viyash Scientific have too much debt? Viyash Scientific Ltd had ₹490 Cr of borrowings against ₹2,911 Cr of equity in FY26, so its debt is 0.17× its equity. Its operating profit is 10 times its interest bill. Over 5 years borrowings went from ₹277 Cr to ₹490 Cr. Over the last 3 of those years it spent ₹2,048 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 362% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Viyash Scientific shareholding pattern? Foreign institutions cut their stake in Viyash Scientific Ltd by 3.9 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 2.6% of the company. Promoters moved −3.5 points over the same period, to 49.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −3.9 points over 8 quarters, to 2.6%; Promoters: −3.5 points over 8 quarters, to 49.2%; Domestic institutions: −1.7 points over 8 quarters, to 8.3%. Why the owners changed: foreign institutions drove it (−3.9 points), together with promoters (−3.5 points). They reduced their stake. ## How far is Viyash Scientific from balance-sheet trouble? For Viyash Scientific Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Viyash Scientific rank in its industry? 64.2 out of 100, rank 3 of 3 in Pharma - Animal, with 79% of the evidence available. Viyash Scientific Ltd scores 64.2 out of 100 against the 3 companies it is compared with in Pharma - Animal, ranking 3. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 32.6 + 12.7 + 11.5 + 7.4 = 64.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Viyash Scientific compared with? Viyash Scientific ranks 3 of 3 Pharma - Animal companies on the 4-Factor Sector Score, with 64.2 out of 100. 1. [NGL Fine Chem Ltd](https://www.sectoralpha.in/stocks/ngl-fine-chem-ltd) NGLFINE · quiet · Most evidence points up · 97% evidence 75.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 35.0/35 · Revenue 40.7% · Profit 100% · Operating margin change 6 points · 100% evidence Capital efficiency 18.3/25 · ROCE 18.6% · Operating margin 17% · 100% evidence Valuation 14.8/20 · P/E 27.3× · PEG 0.62 · 85% evidence Relative strength 7.8/20 · Lead over its industry -1.9% · Lead over NIFTY 500 12.6% · 1 year 69.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 35 + 18.3 + 14.8 + 7.8 = 75.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Hester Biosciences Ltd](https://www.sectoralpha.in/stocks/hester-biosciences-ltd) HESTERBIO · turning · Most evidence points up · 64% evidence 68.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.4/35 · Revenue 3.8% · Profit 100% · Operating margin change 2 points · 95% evidence Capital efficiency 16.5/25 · ROCE 15.2% · Operating margin 29% · 76% evidence Valuation 12.2/20 · P/E 36.7× · PEG n/a · 35% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 30% · 1 year 43.4% · 25% evidence · 6 of 12 weeks ahead Exact sum: 27.4 + 16.5 + 12.2 + 12.5 = 68.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. Viyash Scientific Ltd this page VIYASH · quiet · Evidence leans up · 79% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.6/35 · Revenue 52.9% · Profit 100% · Operating margin change 4 points · 95% evidence Capital efficiency 12.7/25 · ROCE 13.4% · Operating margin 19% · 76% evidence Valuation 11.5/20 · P/E 43.5× · PEG n/a · 35% evidence Relative strength 7.4/20 · Lead over its industry -16.1% · Lead over NIFTY 500 0% · 1 year 1.8% · 100% evidence · 2 of 12 weeks ahead Exact sum: 32.6 + 12.7 + 11.5 + 7.4 = 64.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Animal](https://www.sectoralpha.in/sectors/pharma-animal), all 3 compared on one page. ## Which companies are close to Viyash Scientific in size? Viyash Scientific is the largest of 3 Pharma - Animal companies on Sector Alpha by market value (scores of 30 October 2026). It is the largest. Just below it: Hester Biosciences and NGL Fine Chem. ### Pharma - Animal companies close in size

1. Viyash Scientific Ltd ₹9,648 crore
2. [Hester Biosciences Ltd](https://www.sectoralpha.in/stocks/hester-biosciences-ltd) ₹1,947 crore
3. [NGL Fine Chem Ltd](https://www.sectoralpha.in/stocks/ngl-fine-chem-ltd) ₹1,561 crore

[All 3 Pharma - Animal companies, largest first](https://www.sectoralpha.in/sectors/pharma-animal#all-companies)

### Companies close in size in other industries

1. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) ₹9,851 crore · Pharma - Formulators
2. [India Cements Ltd](https://www.sectoralpha.in/stocks/india-cements-ltd) ₹9,672 crore · Cement
3. Viyash Scientific Ltd ₹9,648 crore
4. [Techno Electric & Engineering Company Ltd](https://www.sectoralpha.in/stocks/techno-electric-engineering-company-ltd) ₹9,645 crore · Data Centre
5. [Can Fin Homes Ltd](https://www.sectoralpha.in/stocks/can-fin-homes-ltd) ₹9,582 crore · Finance - Housing

## What else do people ask about Viyash Scientific? ### What is Viyash Scientific's share price today? Viyash Scientific Ltd's share price is ₹219.45, +2.3% over the past year. The whole company is worth ₹9,712 Cr on the market. In the last 52 weeks it traded between ₹188 to ₹294; today it is 30% of the way up from the low, 6.5% below its 200-day average (as of 3 November 2026). ### What were Viyash Scientific's latest quarterly results? Viyash Scientific Ltd reported revenue of ₹946 Cr and net profit of ₹79.0 Cr for the Jun 2026 quarter. Revenue rose 19.4% and profit rose 113.5% compared with a year earlier. Earnings per share were ₹1.51. The operating margin was 19.0%, 4.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Viyash Scientific's market cap? Viyash Scientific Ltd's market capitalisation is ₹9,712 Cr at a share price of ₹219.45. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Viyash Scientific performing? Viyash Scientific Ltd's share price has been rising for 74 weeks. In its latest quarter, revenue rose 19.4% and profit rose 113.5% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 9 weeks running (as of 3 November 2026). ### Will Viyash Scientific's share price go up? This page does not forecast Viyash Scientific Ltd's share price. What it shows instead: the share price is ₹219.45, and it has been rising for 74 weeks. Its P/E of 43.8× is higher than 27% of its own last 9 years (as of 3 November 2026). ### Who owns Viyash Scientific? Promoters own 49.2% of Viyash Scientific Ltd, foreign institutions 2.6%, domestic institutions 8.3% and the public 39.8% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 3.9 percentage points over 8 quarters (as of 3 November 2026). ### Where is Viyash Scientific in its business cycle? Viyash Scientific Ltd's FY26 operating margin was 19.0%, against a 13-year range of 0.8% to 19.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 19.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Viyash Scientific story? The main question: yearly earnings per share moved +336.6% while the share price moved +2.3%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Viyash Scientific a stock worth studying right now? What the numbers show: Viyash Scientific Ltd's results are improving, while its P/E is near the low end of its own history over 9 years, higher than only 27% of past readings. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Viyash Scientific share price forecast for 2026? What management itself guided: Consolidated operating margin around 20-22%, with US human-formulations margin expected to continue at the current level. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.